Compare Mesoblast Limited (MESO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Redwire Corporation — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Redwire Corporation trades at $9.57 (market cap $2.44B). The key difference: Redwire Corporation is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 11,053,212). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Redwire Corporation for 18 Days on average.
| MESO | RDW | |
|---|---|---|
Market Cap | $1.75B | $2.44B |
Volume | 239,027 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $20.96 | $25.90 |
52-Week Low | $13.19 | $5.06 |
Typical Hold Time | 15 Days | 18 Days |
Enterprise Value | $1.83B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Redwire Corporation (RDW) trades at $9.57, down 6.54% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, though revenue growth remains strong at 89.6% year-over-year. Recent developments include a $980 million Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
Despite strong analyst support (80% buy ratings) and a $14.88 price target suggesting 55% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents high-risk speculation on space infrastructure growth, dependent on successful execution and SpaceX's Starship development timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
